Keyphrases
COVID-19
63%
Antiretroviral Therapy
40%
Confidence Interval
39%
AIDS/HIV
36%
People Living with HIV (PLHIV)
34%
Virus
34%
West Nile Virus
33%
Clostridium Difficile Infection
30%
United States
29%
HIV Patients
23%
Risk Factors
23%
Monoclonal Antibody
23%
Lymphatic Filariasis
22%
West Nile Virus Infection
20%
Plasmodium Falciparum
20%
T Cells
18%
Antibiotics
18%
Interferon-α (IFN-α)
18%
Central Nervous System
17%
Surgical Site Infection
16%
Nematodes
16%
Microfilaria
16%
Zika Virus
16%
HIV Care
16%
Infectious Diseases
15%
Enterotoxigenic Escherichia Coli
15%
Epidemiology
14%
Mass Drug Administration
14%
Intensive Care Unit
14%
Odds Ratio
14%
Human Immunodeficiency Virus Type 1 (HIV-1)
14%
Epitope
14%
Viral Infection
14%
Dengue Virus
14%
Mycobacterium Tuberculosis (M. tb)
14%
Infection Rate
13%
Escherichia Coli
13%
Flavivirus
13%
Immune Response
13%
CD8+ T Cells
12%
HIV Infection
12%
Neutralizing Antibodies
12%
Brugia Malayi
12%
Albendazole
12%
Chikungunya Virus (CHIKV)
11%
Bloodstream Infection
11%
Ivermectin
11%
Vaccination
11%
Dendritic Cells
11%
Hospitalization
11%
Influenza Virus
11%
Zambia
11%
Diethylcarbamazine
10%
Lung
10%
Emergency Department
10%
High Risk
10%
Antimicrobial Resistance
10%
Infection Prevention
10%
Clostridioides Difficile
10%
Nigeria
10%
Innate Immune Response
10%
Macrophages
10%
Randomized Controlled Trial
10%
Sub-Saharan Africa
10%
COVID-19 Pandemic
10%
Hemoglobin
9%
Methicillin-resistant Staphylococcus Aureus
9%
Hospitalized Patients
9%
Clinical Outcomes
9%
Missouri
9%
Parasitic Nematode
9%
Wuchereria Bancrofti
9%
Antibody Response
9%
Onchocerca Volvulus
9%
Filarial
9%
Recombinant
9%
Tuberculosis
9%
Malaria Parasite
9%
Meta-analysis
9%
Onchocerciasis
9%
Tertiary Care Hospital
9%
Filariasis
9%
Urinary Tract Infection
8%
Adjusted Odds Ratio
8%
Health Personnel
8%
Inflammation
8%
Microbiota
8%
CD4 Count
8%
Plasmepsin
8%
Viral
8%
Healthcare
8%
Antimicrobial
8%
Type I Interferon
8%
Alphavirus
8%
Bancroftian Filariasis
8%
Sepsis
8%
Difficile
8%
Healthcare Workers
8%
Virus Infection
8%
Pre-exposure Prophylaxis (PrEP)
8%
Immunology and Microbiology
Viral Disease
54%
Human Immunodeficiency Virus
44%
Virus
40%
West Nile Virus
38%
Infectious Agent
35%
Severe Acute Respiratory Syndrome Coronavirus 2
34%
interferon
29%
T Cell
26%
Monoclonal Antibody
20%
Nematode
20%
Epitope
19%
Human Immunodeficiency Virus 1
17%
Cytotoxic T-Cell
17%
Immune Response
17%
Plasmodium falciparum
17%
Escherichia coli
17%
Macrophage
15%
Prevalence
15%
Neutralizing Antibody
15%
Central Nervous System
14%
Dengue Virus
14%
Neutralization
14%
Plasmodium
13%
Filariasis
13%
Flavivirus
13%
Zika Virus
12%
Enterotoxigenic Escherichia Coli
12%
Viral Replication
12%
Lymphatic Filariasis
12%
Dendritic Cell
12%
Mycobacterium Tuberculosis
11%
Peptides
11%
Innate Immune System
11%
COVID-19
11%
Antibody Response
11%
Brugia malayi
10%
Spike
10%
Peptoclostridium difficile
10%
B Cell
10%
Chikungunya Virus
9%
Microbiome
9%
Neutrophil
9%
Alphavirus
9%
Glycoprotein
9%
Microflora
9%
Blood Plasma
9%
Viral Load
9%
Human Immunodeficiency Virus Infection
9%
Cytokine
8%
Influenza
8%
Serotype
8%
Microorganism
8%
Hemoglobin
8%
Staphylococcus Aureus
7%
T-Helper Cell
7%
Norovirus
7%
RNA Virus
7%
Intestine Flora
7%
Wuchereria bancrofti
7%
Wild Type
7%
Microfilaria (Nematode Larva)
7%
Lymph Node
7%
Antimicrobial Resistance
7%
Albendazole
7%
Gene Expression
7%
Plasmepsin
7%
Murine Norovirus
7%
Parasitic Nematodes
7%
Ebola Virus
7%
Host Cell
7%
CD4 Lymphocyte Count
7%
CD4
7%
Diethylcarbamazine
7%
Amino Acid
7%
Influenza Virus
6%
Methicillin-Resistant Staphylococcus Aureus
6%
Urinary Tract
6%
Adaptive Immune System
6%
Microfilaria
6%
Receptor Binding
6%
Helminth
6%
Wolbachia
6%
Onchocerca volvulus
6%
Lineages
6%
Mouse Model
6%
Onchocerciasis
6%
Human Monoclonal Antibody
6%
Amino Terminal Sequence
6%
Dynamics
5%
Influenzavirus A
5%
Blood Brain Barrier
5%
Omicron Coronavirus Variant
5%
Secretion (Process)
5%
Maturation
5%
Virion
5%
Erythrocyte
5%
Cytotoxic T Cell
5%
Myeloid
5%
Cytomegalovirus
5%
Transcription Factors
5%
Medicine and Dentistry
Human Immunodeficiency Virus
100%
Infection
86%
Diseases
37%
COVID-19
37%
Severe Acute Respiratory Syndrome Coronavirus 2
28%
Antiretroviral Therapy
26%
Prevalence
20%
Infectious Disease
17%
Cohort Effect
17%
Lymphatic Filariasis
17%
Clostridium Difficile Infection
16%
Bloodstream Infection
16%
Pathogen
16%
Odds Ratio
15%
Surgical Infection
15%
Virus
13%
Antibiotics
13%
Intensive Care Unit
13%
Antiinfective Agent
12%
Health Care Cost
12%
Systematic Review
11%
Public Health
11%
Drug Administration
10%
Randomized Controlled Trial
10%
Emergency Department
10%
Clinician
10%
Human Immunodeficiency Virus Infection
9%
Infection Prevention
9%
Virus Infection
9%
Health Care
8%
Sepsis
8%
Ivermectin
8%
Antibiotic Resistance
8%
Outpatient
8%
Albendazole
8%
Interferon
7%
Onchocerciasis
7%
Comorbidity
7%
Clinical Trial
7%
Cohort Analysis
7%
Lung
7%
Tertiary Care
7%
Infection Rate
6%
Meta-Analysis
6%
Adverse Event
6%
Urinary Tract Infection
6%
In Vitro
6%
Logistic Regression Analysis
6%
Antivirus Agent
6%
Hazard Ratio
6%
T Cell
6%
Antibiotic Therapy
6%
Low and Middle Income Countries
6%
Diethylcarbamazine
6%
Onchocerca volvulus
5%
Central Nervous System
5%
Zika Virus
5%
Peptoclostridium difficile
5%
Pediatrics
5%
Infection Control
5%
Cardiovascular Disease
5%
Antimicrobial Therapy
5%
Drug Use
5%
Cytomegalovirus Infection
5%
Coronavirinae
5%
Placebo
5%
Emergency Care
5%
Healthcare Associated Infection
5%
Catheter Infection
5%
Immune Response
5%
Retrospective Cohort Study
5%
Cross Sectional Study
5%
West Nile Virus
5%
Cytomegalovirus
5%